PETER A WARD, MD
Medical Practice in Ann Arbor, MI
License number
Michigan 4301024401
Category
Medical Practice
Type
Immunopathology
License number
Michigan 4301024401
Category
Medical Practice
Type
Anatomic Pathology
Address
Address
1500 Floor University Hospital Recp Pathology, Ann Arbor, MI 48109
Phone
(800) 862-7284
(734) 936-2047
(734) 936-2047
Personal information
See more information about PETER A WARD at radaris.comName
Address
Phone
4900 Walnut Woods Dr, Ann Arbor, MI 48105
4401 Cherrytree Ln, Flint, MI 48507
350 Bruin Lake Rd, Gregory, MI 48137
Professional information
Anti-Inflammatory Agent
US Patent:
5872109, Feb 16, 1999
Filed:
Oct 4, 1996
Appl. No.:
8/722131
Inventors:
Kazuo Akima - Yokohama, JP
Peter A. Ward - Ann Arbor MI
Masayuki Miyasaka - Suita, JP
Yasuo Suzuki - Shizuoka, JP
Peter A. Ward - Ann Arbor MI
Masayuki Miyasaka - Suita, JP
Yasuo Suzuki - Shizuoka, JP
Assignee:
Shiseido Company, Ltd.
International Classification:
A01N 4304, C07H 504
US Classification:
514 54
Abstract:
Use of a polysaccharide selected from the group consisting of sulfated acid mucopolysaccharides and sulfated dextrans, and physiologically acceptable salts thereof for prophylaxis or treatment of inflammations, particularly an adult respiratory distress syndrome (ARDS), ischemic heart diseases, ischemic cerebral diseases, chronic articular rheumatism, atopic dermatitis, and infiltration after organ implantation.
Dr. Peter A Ward, Ann Arbor MI - MD (Doctor of Medicine)
Specialties:
Immunopathology
Address:
University Of Michigan Pthlgy
1500 E Medical Center Dr SUITE 5014, Ann Arbor 48109
(734) 936-6770 (Phone)
1500 E Medical Center Dr SUITE 5014, Ann Arbor 48109
(734) 936-6770 (Phone)
Certifications:
Anatomic Pathology, 1964, Immunopathology, 1983, Pathology Recertification, 1997
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
University Of Michigan Pthlgy
1500 E Medical Center Dr SUITE 5014, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
1500 E Medical Center Dr SUITE 5014, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
Education:
Medical School
University of Mi Med Sch
Graduated: 1960
Bellevue Hospital Center
University Of Michigan Hospitals
Scripps Clin Rsch Fdn
University of Mi Med Sch
Graduated: 1960
Bellevue Hospital Center
University Of Michigan Hospitals
Scripps Clin Rsch Fdn
Compositions And Methods For The Treatment Of Sepsis
US Patent:
6673346, Jan 6, 2004
Filed:
Aug 31, 1999
Appl. No.:
09/387671
Inventors:
Peter A. Ward - Ann Arbor MI
Markus Huber-Lang - South Lyon MI
Vidya Sarma - Ann Arbor MI
Boris Czermak - Frieburg, DE
Markus Huber-Lang - South Lyon MI
Vidya Sarma - Ann Arbor MI
Boris Czermak - Frieburg, DE
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 39395
US Classification:
4241581, 4241301, 4241391, 4241721, 5303892, 5303893
Abstract:
The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5 antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5 antibodies employing C-terminal truncated C5 peptides.
Sulfatides As Anti-Inflammatory Compounds
US Patent:
5486536, Jan 23, 1996
Filed:
Aug 15, 1994
Appl. No.:
8/289585
Inventors:
Peter A. Ward - Ann Arbor MI
Masayuka Miyasaka - Suita, JP
Yasuo Suzuki - Shizuoka, JP
Masayuka Miyasaka - Suita, JP
Yasuo Suzuki - Shizuoka, JP
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 3135
US Classification:
514460
Abstract:
Using in vitro adhesion of recombinant rat L-selectin-Ig or rat neutrophils, it has been demonstrated that these materials bind to sulfatide that has been present in solid phase on a plastic surface. The binding activity appears to have structural requirements, with the sulfate group being critically present in position 3 on the pyranose ring of galactose. When used in vivo, it has been demonstrated that sulfated glycolipids such as brain sulfatide and ganglioside, have significantly protective effects in two models of lung inflammation, the first systemic activation of complement and the second occurring after intrapulmonary deposition of immune complexes. Both inflammatory reactions are complement, neutrophil and selectin-dependent. The protective effects of these compounds are linked to their ability to prevent the recruitment of neutrophils into lung tissue. On the basis of these findings, it is demonstrated by sulfatides and related compounds have significant in vivo anti-inflammatory activities.
Compositions And Methods For The Treatment Of Sepsis
US Patent:
6866845, Mar 15, 2005
Filed:
Aug 30, 2000
Appl. No.:
09/651685
Inventors:
Peter A. Ward - Ann Arbor MI, US
Markus Huber-Lang - South Lyon MI, US
Vidya Sarma - Ann Arbor MI, US
Markus Huber-Lang - South Lyon MI, US
Vidya Sarma - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K039/395, C07K016/18
US Classification:
4241391, 5303879, 53038825, 5303893
Abstract:
The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5a antibodies employing C-terminal truncated C5a peptides.
Compositions And Methods For The Treatment Of Sepsis
US Patent:
6987166, Jan 17, 2006
Filed:
Jun 11, 2001
Appl. No.:
09/878603
Inventors:
Peter A. Ward - Ann Arbor MI, US
Markus Huber-Lang - South Lyon MI, US
Vidya Sarma - Ann Arbor MI, US
Boris Czermak - Frieburg, DE
Markus Huber-Lang - South Lyon MI, US
Vidya Sarma - Ann Arbor MI, US
Boris Czermak - Frieburg, DE
Assignee:
The Regents of the Univeristy of Michigan - Ann Arbor MI
International Classification:
A61K 39/00, A61K 47/00, C07K 7/06
US Classification:
530328, 530329, 530330, 4241851, 4242781
Abstract:
The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5a antibodies employing C-terminal truncated C5a peptides.
Compositions And Methods For The Diagnosis And Treatment Of Sepsis
US Patent:
7455837, Nov 25, 2008
Filed:
Nov 5, 2003
Appl. No.:
10/701871
Inventors:
Renfeng Guo - Ann Arbor MI, US
Niels C. Riedemann - Hannover, DE
Peter A. Ward - Ann Arbor MI, US
Markus Huber-Lang - Blaustein-Arnegg, DE
J. Vidya Sarma - Ann Arbor MI, US
Niels C. Riedemann - Hannover, DE
Peter A. Ward - Ann Arbor MI, US
Markus Huber-Lang - Blaustein-Arnegg, DE
J. Vidya Sarma - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 39/395, A61K 39/00, A61K 38/16
US Classification:
4241431, 4241391, 514 8, 514921
Abstract:
The present invention relates to methods and compositions for the diagnosis and treatment of sepsis. The present invention also provides methods of providing a prognosis to a patient with sepsis. In particular, the present invention relates to compositions and methods for the detection of C5aR expression and the correlation of C5aR expression level with prognosis in sepsis.
Compositions And Methods For The Threatment Of Sepsis
US Patent:
2006015, Jul 20, 2006
Filed:
Sep 27, 2005
Appl. No.:
11/236188
Inventors:
Peter Ward - Ann Arbor MI, US
Markus Huber-Lang - Blaustein-Markbonn, DE
Vidya Sarma - Ann Arbor MI, US
Boris Czermak - Zurich, CH
Markus Huber-Lang - Blaustein-Markbonn, DE
Vidya Sarma - Ann Arbor MI, US
Boris Czermak - Zurich, CH
Assignee:
The Regents of The University Of Michigan - Ann Arbor MI
International Classification:
A61K 39/395
US Classification:
424144100
Abstract:
The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5a antibodies employing C-terminal truncated C5a peptides.
Peter D. Ward, Ann Arbor MI - Lawyer
Address:
317 S Division St STE 66, Ann Arbor 48104
(734) 476-5476
(734) 476-5476
Licenses:
Michigan - Active And In Good Standing 1990